Hepatic Encephalopathy: Pharmacological Therapies Targeting Ammonia

 

 Permissions and Reprints

Abstract

Hepatic encephalopathy (HE) is a major complication in patients with decompensated cirrhosis, leading to higher readmission rates causing a profound burden of disease and considerable health care costs. Because ammonia is thought to play a crucial role in the pathogenesis of HE, therapies directed at reducing ammonia levels are now being aggressively developed. Ammonia scavengers such as AST-120 (spherical carbon adsorbent), glycerol phenylbutyrate, sodium phenylacetate or sodium benzoate, and ornithine phenylacetate have been used to improve HE symptoms. A new approach, bowel cleansing with polyethylene glycol 3350, appears to be a promising therapy, with a recent study demonstrating a more rapid improvement in overt HE (at 24 hours after treatment) than lactulose. Extracorporeal devices, although now used primarily in research settings, have also been utilized in patients with refractory HE, but are not approved for clinical management.

• References

• 1 Wong RJ, Gish RG, Ahmed A. Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation. Liver Transpl 2014; 20 (12) 1454-1461
  PubMedGoogle Scholar
• 2 Blei AT, Córdoba J ; Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol 2001; 96 (7) 1968-1976
  CrossrefPubMedGoogle Scholar
• 3 Vince AJ, Burridge SM. Ammonia production by intestinal bacteria: the effects of lactose, lactulose and glucose. J Med Microbiol 1980; 13 (2) 177-191
  CrossrefPubMedGoogle Scholar
• 4 Floch MH, Katz J, Conn HO. Qualitative and quantitative relationships of the fecal flora in cirrhotic patients with portal systemic encephalopathy and following portacaval anastomosis. Gastroenterology 1970; 59 (1) 70-75
  PubMedGoogle Scholar
• 5 Wolpert E, Phillips SF, Summerskill WH. Ammonia production in the human colon. Effects of cleansing, neomycin and acetohydroxamic acid. N Engl J Med 1970; 283 (4) 159-164
  CrossrefPubMedGoogle Scholar
• 6 Plauth M, Roske AE, Romaniuk P, Roth E, Ziebig R, Lochs H. Post-feeding hyperammonaemia in patients with transjugular intrahepatic portosystemic shunt and liver cirrhosis: role of small intestinal ammonia release and route of nutrient administration. Gut 2000; 46 (6) 849-855
  CrossrefPubMedGoogle Scholar
• 7 Olde Damink SW, Jalan R, Redhead DN, Hayes PC, Deutz NE, Soeters PB. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 2002; 36 (5) 1163-1171
  CrossrefPubMedGoogle Scholar
• 8 Romero-Gómez M, Ramos-Guerrero R, Grande L , et al. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J Hepatol 2004; 41 (1) 49-54
  CrossrefPubMedGoogle Scholar
• 9 Romero-Gómez M, Jover M, Del Campo JA , et al. Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. Ann Intern Med 2010; 153 (5) 281-288
  CrossrefPubMedGoogle Scholar
• 10 Häussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?. J Hepatol 2000; 32 (6) 1035-1038
  CrossrefPubMedGoogle Scholar
• 11 Ghabril M, Zupanets IA, Vierling J , et al. Glycerol phenylbutyrate in patients with cirrhosis and episodic hepatic encephalopathy: a pilot study of safety and effect on venous ammonia concentration. Clin Pharm Drug Dev 2013; 2: 278-284
  PubMedGoogle Scholar
• 12 Rockey DC, Vierling JM, Mantry P , et al; HALT-HE Study Group. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology 2014; 59 (3) 1073-1083
  CrossrefPubMedGoogle Scholar
• 13 Lee B, Rhead W, Diaz GA , et al. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. Mol Genet Metab 2010; 100 (3) 221-228
  CrossrefPubMedGoogle Scholar
• 14 McGuire BM, Zupanets IA, Lowe ME , et al. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology 2010; 51 (6) 2077-2085
  CrossrefPubMedGoogle Scholar
• 15 Diaz GA, Krivitzky LS, Mokhtarani M , et al. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. Hepatology 2013; 57 (6) 2171-2179
  CrossrefPubMedGoogle Scholar
• 16 Lichter-Konecki U, Diaz GA, Merritt II JL , et al. Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate. Mol Genet Metab 2011; 103 (4) 323-329
  CrossrefPubMedGoogle Scholar
• 17 Smith W, Diaz GA, Lichter-Konecki U , et al. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate. J Pediatr 2013; 162 (6) 1228-1234 , 1234.e1
  CrossrefPubMedGoogle Scholar
• 18 Jalan R, Wright G, Davies NA, Hodges SJ. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Med Hypotheses 2007; 69 (5) 1064-1069
  CrossrefPubMedGoogle Scholar
• 19 Ventura-Cots M, Arranz JA, Simón-Talero M , et al. Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study. J Clin Gastroenterol 2013; 47 (10) 881-887
  CrossrefPubMedGoogle Scholar
• 20 Córdoba J, Ventura-Cots M. Drug-induced removal of nitrogen derivatives in urine: a new concept whose time has come. Hepatology 2014; 59 (3) 764-766
  CrossrefPubMedGoogle Scholar
• 21 Shoji T, Wada A, Inoue K , et al. Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal function. Nephron Clin Pract 2007; 105 (3) c99-c107
  CrossrefPubMedGoogle Scholar
• 22 Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006; 47 (4) 565-577
  CrossrefPubMedGoogle Scholar
• 23 Sanaka T, Sugino N, Teraoka S, Ota K. Therapeutic effects of oral sorbent in undialyzed uremia. Am J Kidney Dis 1988; 12 (2) 97-103
  CrossrefPubMedGoogle Scholar
• 24 Owada A, Nakao M, Koike J, Ujiie K, Tomita K, Shiigai T. Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study. Kidney Int Suppl 1997; 63: S188-S190
  PubMedGoogle Scholar
• 25 Shen B, Pardi DS, Bennett AE , et al. The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis. Am J Gastroenterol 2009; 104 (6) 1468-1474
  CrossrefPubMedGoogle Scholar
• 26 Hiraishi M. The effect of oral adsorbent on surgically induced hepatic failure. Jpn J Surg 1987; 17 (6) 517-527
  CrossrefPubMedGoogle Scholar
• 27 Pockros P, Hassanein T, Vierling J , et al. Phase 2, multicenter, randomized study of ast-120 (spherical carbon adsorbent) vs. lactulose in the treatment of low-grade hepatic encephalopathy (HE). J Hepatol 2009; 50: S43-S44
  PubMedGoogle Scholar
• 28 Bosoi CR, Parent-Robitaille C, Anderson K, Tremblay M, Rose CF. AST-120 (spherical carbon adsorbent) lowers ammonia levels and attenuates brain edema in bile duct-ligated rats. Hepatology 2011; 53 (6) 1995-2002
  CrossrefPubMedGoogle Scholar
• 29 Kundra A, Jain A, Banga A, Bajaj G, Kar P. Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension. Clin Biochem 2005; 38 (8) 696-699
  CrossrefPubMedGoogle Scholar
• 30 Palm K, Luthman K, Ros J, Grasjo J, Artursson P. Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. J Pharmacol Exp Ther 1999; 291 (2) 435-443
  PubMedGoogle Scholar
• 31 Bajaj JS, Sheikh MY, Chojkier M , et al. AST-120 (spherical carbon adsorbent) in covert hepatic encephalopathy: results of the astute trial. J Hepatol 2013; 58 (5): S84
  PubMedGoogle Scholar
• 32 Hassanein TI, Tofteng F, Brown Jr RS , et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46 (6) 1853-1862
  CrossrefPubMedGoogle Scholar
• 33 Hill K, Hu KQ, Cottrell A, Teichman S, Hillebrand DJ. Charcoal-based hemodiabsorption liver support for episodic type C hepatic encephalopathy. Am J Gastroenterol 2003; 98 (12) 2763-2770
  CrossrefPubMedGoogle Scholar
• 34 Tsipotis E, Shuja A, Jaber BL. Albumin dialysis for liver failure: a systematic review. Adv Chronic Kidney Dis 2015; 22 (5) 382-390
  CrossrefPubMedGoogle Scholar
• 35 Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol 3350–electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med 2014; 174 (11) 1727-1733
  CrossrefPubMedGoogle Scholar
• 36 Hammer HF, Santa Ana CA, Schiller LR, Fordtran JS. Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose. J Clin Invest 1989; 84 (4) 1056-1062
  CrossrefPubMedGoogle Scholar
• 37 Rahimi RS, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol for treatment of hepatic encephalopathy: reply. JAMA Intern Med 2015; 175 (5) 868-869
  CrossrefPubMedGoogle Scholar